| Drug Type Small molecule drug | 
| Synonyms AL 2846, AL2846 | 
| Target | 
| Action inhibitors | 
| Mechanism c-Met inhibitors(Hepatocyte growth factor receptor inhibitors) | 
| Therapeutic Areas | 
| Inactive Indication | 
| Originator Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePhase 3 | 
| First Approval Date- | 
| RegulationSpecial Review Project (China) | 
| Molecular FormulaC36H36F2N4O5 | 
| InChIKeyIXDALXNUFGTEMF-UHFFFAOYSA-N | 
| CAS Registry1363402-44-1 | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Refractory Differentiated Thyroid Gland Carcinoma | Phase 3 | China  | 24 Mar 2025 | |
| Refractory Differentiated Thyroid Gland Carcinoma | Phase 3 | China  | 24 Mar 2025 | |
| Advanced Lung Non-Small Cell Carcinoma | Phase 3 | China  | 05 Jun 2023 | |
| Ovarian Cancer | Phase 2 | China  | 15 Feb 2023 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | China  | 03 Feb 2023 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | China  | 03 Feb 2023 | |
| Neoplasms | Phase 2 | China  | 30 Jan 2022 | |
| Neurofibromatosis 1 | Phase 2 | China  | 07 Sep 2021 | |
| Neurofibrosarcoma | Phase 2 | China  | 07 Sep 2021 | |
| Bone metastases | Phase 2 | China  | 24 Sep 2020 | 
| NCT05745363 (ESMO2024) Manual | Phase 1 | 28 | AL2846 90mg | ezxaeasvjv(vytofzkitz) = nlrfvzlqen hfvpnurgen (igjkqvwebz ) View more | Positive | 16 Sep 2024 | |
| Phase 1 | 33 | xyedsiudlf(uvrageyznv) = wkgomhqsuv xghhdjxzuw (iiuojkziix, 3.1 - 32.8) View more | Positive | 15 Sep 2024 | |||
| xyedsiudlf(uvrageyznv) = fmprmwtdar xghhdjxzuw (iiuojkziix ) View more | |||||||
| NCT06116240 (WCLC2024) Manual | Phase 1 | Non-Small Cell Lung Cancer Second line | 44 | gkmudqczbt(fglzothbqw) = gjpgrjmcon efkukxjjct (uiaqqmroej ) View more | Positive | 09 Sep 2024 | |
| Phase 1 | 15 | AL2846 + Gemcitabine | egylrmtbad(hlnoywjcmo) = brcofjvzht rfkswjeult (vyjovegnhd ) View more | - | 28 May 2021 | 





